Response to letter regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: Analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials"

Stroke

Volumn 46, Issue 2, 2014, Pages e45-

  Rao, Neal Matsumori ^a   Levine, Steven R ^b   Saver, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ALGORITHM; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; FIBRINOLYTIC THERAPY; HEMATOMA; HUMAN; LETTER; PHYSICIAN; PRIORITY JOURNAL; REGISTER; TOTAL QUALITY MANAGEMENT; CEREBRAL HEMORRHAGE; PROCEDURES; STANDARDS; STROKE;

CEREBRAL HEMORRHAGE; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84940376880     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007860     Document Type: Letter

References (5)

1. Turc G, Tisserand M, Seners P, Oppenheim C, Baron J-C. Letter by Turc et al regarding article, "Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke Tissue-Type Plasminogen Activator Trials." Stroke. 2015;46:e43-e44. doi: 10.1161/STROKEAHA.114.007747.
2. Rao NM, Levine SR, Gornbein JA, Saver JL. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke. 2014;45:2728-2733. doi: 10.1161/STROKEAHA.114.005135.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
4. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. doi: 10.1016/S0140-6736(07)60149-4.
5. Strbian D, Sairanen T, Meretoja A, Pitkäniemi J, Putaala J, Salonen O, et al; Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011;77:341-348. doi: 10.1212/WNL. 0b013e3182267b8c.